RCM
ASMB icon

RA Capital Management’s Assembly Biosciences ASMB Stock Holding History

RA Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28M Hold
1,020,410
– – 0.24% 56
2026
Q1 		$28.3M Hold
1,020,410
– – 0.3% 48
2025
Q4 		$34.7M Hold
1,020,410
– – 0.36% 43
2025
Q3 		$26.1M Buy
+1,020,410
New +$22.4M 0.32% 39

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $606M AUM

RA Capital Management's ASMB Position: Q2 2026 in Review

RA Capital Management held its Assembly Biosciences (ASMB) position steady in Q2 2026 at 1,020,410 shares worth $28M. The position accounts for 0.24% of the portfolio, ranked #56.

RA Capital Management first reported a position in ASMB in Q3 2025 and has held it in 4 quarters since. The position peaked at $34.7M in Q4 2025. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • RA Capital Management held 1,020,410 shares of Assembly Biosciences worth $28M as of Q2 2026.
  • RA Capital Management left its Assembly Biosciences share count unchanged in Q2 2026.
  • Assembly Biosciences made up 0.24% of RA Capital Management's portfolio in Q2 2026, its #56 holding.
  • RA Capital Management first reported a position in Assembly Biosciences in Q3 2025 and has held it in 4 quarters since.
  • RA Capital Management's Assembly Biosciences position peaked at $34.7M in Q4 2025.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.